Movement Alert｜CSPC Pharmaceutical Rises 3.29% in Regular Trading, Core ADC Pipeline SYS6010 Initiates Phase III Clinical Trial

Market Focus06-29 10:05

On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.

On the news front, CSPC Pharmaceutical recently announced that its core ADC drug SYS6010 in combination with enlonstobart for first-line treatment of driver-gene-negative non-small cell lung cancer has officially commenced a Phase III clinical study in China, with the first subject enrollment planned for July. SYS6010 is an EGFR-targeting antibody-drug conjugate. Prior Phase I/II data demonstrated an objective response rate of 41.8% and a disease control rate of 81.4% among 533 evaluable patients, showcasing favorable anti-tumor activity.

The broader pharmaceutical sector also rallied, with Hengrui Pharma up 4.72%, Luye Pharma up 5.06%, and Hansoh Pharma up 3.21%, providing additional sectoral support to the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179003722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179003722","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Rises 3.29% in Regular Trading, Core ADC Pipeline SYS6010 Initiates Phase III Clinical Trial","media":"Market Focus","content":"<p><p>On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.</p><p>On the news front, CSPC Pharmaceutical recently announced that its core ADC drug SYS6010 in combination with enlonstobart for first-line treatment of driver-gene-negative non-small cell lung cancer has officially commenced a Phase III clinical study in China, with the first subject enrollment planned for July. SYS6010 is an EGFR-targeting antibody-drug conjugate. Prior Phase I/II data demonstrated an objective response rate of 41.8% and a disease control rate of 81.4% among 533 evaluable patients, showcasing favorable anti-tumor activity.</p><p>The broader pharmaceutical sector also rallied, with Hengrui Pharma up 4.72%, Luye Pharma up 5.06%, and Hansoh Pharma up 3.21%, providing additional sectoral support to the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Rises 3.29% in Regular Trading, Core ADC Pipeline SYS6010 Initiates Phase III Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Rises 3.29% in Regular Trading, Core ADC Pipeline SYS6010 Initiates Phase III Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.</p><p>On the news front, CSPC Pharmaceutical recently announced that its core ADC drug SYS6010 in combination with enlonstobart for first-line treatment of driver-gene-negative non-small cell lung cancer has officially commenced a Phase III clinical study in China, with the first subject enrollment planned for July. SYS6010 is an EGFR-targeting antibody-drug conjugate. Prior Phase I/II data demonstrated an objective response rate of 41.8% and a disease control rate of 81.4% among 533 evaluable patients, showcasing favorable anti-tumor activity.</p><p>The broader pharmaceutical sector also rallied, with Hengrui Pharma up 4.72%, Luye Pharma up 5.06%, and Hansoh Pharma up 3.21%, providing additional sectoral support to the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1179003722","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179003722","pubTimestamp":1782698752,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.On the news front, CSPC Pharmaceutical recently announced that its core ADC...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"动静快讯|石药制药常规交易涨3.29%核心ADC管线SYS6010启动III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.On the news front, CSPC Pharmaceutical recently announced that its core ADC drug SYS6010 in combination with enlonstobart for first-line treatment of driver-gene-negative non-small cell lung cancer has officially commenced a Phase III clinical study in China, with the first subject enrollment planned for July. SYS6010 is an EGFR-targeting antibody-drug conjugate. Prior Phase I/II data demonstrated an objective response rate of 41.8% and a disease control rate of 81.4% among 533 evaluable patients, showcasing favorable anti-tumor activity.The broader pharmaceutical sector also rallied, with Hengrui Pharma up 4.72%, Luye Pharma up 5.06%, and Hansoh Pharma up 3.21%, providing additional sectoral support to the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179003722","isCrawlerRequest":true}